HU

Hugel, Inc.

Global provider of medical aesthetic solutions like botulinum toxin and HA fillers.

145020 | KO

Overview

Corporate Details

ISIN(s):
KR7145020004
LEI:
Country:
South Korea
Address:
강원특별자치도 춘천시 동내면 거두단지1길 23 -, 춘천시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Hugel, Inc. is a global biopharmaceutical company specializing in the medical aesthetics and therapeutics market. The company develops, manufactures, and sells a range of products, including its flagship botulinum toxin, hyaluronic acid (HA) fillers, skin boosters, and cosmetic threads. Recognized for its advanced technology, Hugel is a leading provider in the aesthetics field, having expanded its presence from its base in South Korea to major international markets such as the USA, Europe, and China. The company focuses on creating value in medical aesthetics by providing high-quality, scientifically-backed solutions for medical professionals and consumers.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-15 00:00
Board/Management Information
대표집행임원변경
Korean 12.6 KB
2025-09-15 00:00
Share Issue/Capital Change
주식매수선택권부여에관한신고
Korean 14.7 KB
2025-09-12 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 7.1 KB
2025-08-29 00:00
Related Party Transaction
대규모기업집단현황공시[분기별공시(개별회사용)]
Korean 8.6 KB
2025-08-26 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.9 KB
2025-08-19 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.1 KB
2025-08-19 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-08-14 00:00
Regulatory News Service
지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항
Korean 11.3 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 4.5 MB
2025-08-14 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.8 KB
2025-08-07 00:00
Regulatory News Service
풍문또는보도에대한해명(미확정)
Korean 11.8 KB
2025-08-06 00:00
Earnings Release
연결재무제표기준영업(잠정)실적(공정공시)
Korean 16.7 KB
2025-08-06 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 7.1 KB
2025-08-06 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 34.5 KB
2025-08-06 00:00
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
Korean 30.2 KB

Automate Your Workflow. Get a real-time feed of all Hugel, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Hugel, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Hugel, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Elicera Therapeutics AB Logo
Develops CAR T-cell & oncolytic virus therapies for cancer, enhanced by its iTANK platform.
Sweden
ELIC
ELI LILLY & Co Logo
Pharma leader developing medicines for diabetes, obesity, oncology, and neuroscience.
United States of America
LLY
Ellen AB Logo
Develops research-based probiotic and prebiotic products for women's intimate health and pH balance.
Sweden
ELN
ELUTIA INC. Logo
Develops drug-eluting biologics to reduce complications from medical implants.
United States of America
ELUT
Emergent BioSolutions Inc. Logo
Develops and manufactures medical countermeasures for public health and national security threats.
United States of America
EBS
ENANTA PHARMACEUTICALS INC Logo
Developing novel small molecule drugs for virology (HCV, RSV) and immunological diseases.
United States of America
ENTA
enGene Holdings Inc. Logo
Developing non-viral, locally administered gene therapies for rare genetic conditions.
United States of America
ENGN
Enliven Therapeutics, Inc. Logo
A clinical-stage biopharma developing kinase inhibitors for precision oncology cancer treatment.
United States of America
ELVN
Enlivex Therapeutics Ltd. Logo
Developing cell therapy that reprograms macrophages to treat immune hyper-responses like sepsis.
United States of America
ENLV
Enlivex Therapeutics Ltd. Logo
Developing cell therapy to restore immune balance for inflammatory diseases like sepsis.
Israel
ENLV

Talk to a Data Expert

Have a question? We'll get back to you promptly.